JP2001503751A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503751A5
JP2001503751A5 JP1998520843A JP52084398A JP2001503751A5 JP 2001503751 A5 JP2001503751 A5 JP 2001503751A5 JP 1998520843 A JP1998520843 A JP 1998520843A JP 52084398 A JP52084398 A JP 52084398A JP 2001503751 A5 JP2001503751 A5 JP 2001503751A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998520843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503751A (ja
JP4175667B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1997/006035 external-priority patent/WO1998019709A2/en
Publication of JP2001503751A publication Critical patent/JP2001503751A/ja
Publication of JP2001503751A5 publication Critical patent/JP2001503751A5/ja
Application granted granted Critical
Publication of JP4175667B2 publication Critical patent/JP4175667B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52084398A 1996-11-04 1997-11-03 トランスフェクションのためのカチオン試薬 Expired - Lifetime JP4175667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3031596P 1996-11-04 1996-11-04
US60/030,315 1996-11-04
PCT/EP1997/006035 WO1998019709A2 (en) 1996-11-04 1997-11-03 Cationic reagents for transfection

Publications (3)

Publication Number Publication Date
JP2001503751A JP2001503751A (ja) 2001-03-21
JP2001503751A5 true JP2001503751A5 (enExample) 2005-03-10
JP4175667B2 JP4175667B2 (ja) 2008-11-05

Family

ID=21853640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52084398A Expired - Lifetime JP4175667B2 (ja) 1996-11-04 1997-11-03 トランスフェクションのためのカチオン試薬

Country Status (7)

Country Link
US (2) US6733777B2 (enExample)
EP (1) EP1003556B1 (enExample)
JP (1) JP4175667B2 (enExample)
AU (1) AU738384B2 (enExample)
CA (1) CA2270396C (enExample)
DE (1) DE69735382T2 (enExample)
WO (1) WO1998019709A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
AU738384B2 (en) * 1996-11-04 2001-09-20 Qiagen Gmbh Cationic reagents for transfection
ES2296419T3 (es) 1998-11-12 2008-04-16 Invitrogen Corporation Reactivos de transfeccion.
US7683035B1 (en) * 1999-02-23 2010-03-23 Qiagen, Gmbh Method of stabilizing and/or isolating nucleic acids
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8242089B2 (en) * 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
US20060257858A1 (en) * 2005-04-01 2006-11-16 Invitrogen Corporation Methods and compositions for introducing biopolymers into cells
MX357691B (es) 2006-01-13 2018-07-19 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
LT2494993T (lt) 2007-05-04 2018-12-27 Marina Biotech, Inc. Aminorūgščių lipidai ir jų panaudojimas
WO2009155100A1 (en) 2008-05-30 2009-12-23 Yale University Targeted oligonucleotide compositions for modifying gene expression
CA2739046A1 (en) 2008-10-16 2010-04-22 Marina Biotech, Inc. Process and compositions for liposomal and effective delivery of nucleic acids
ME03091B (me) 2009-12-01 2019-01-20 Translate Bio Inc Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
FR2964569B1 (fr) 2010-09-10 2012-10-19 Ct De Cooperation Internationale En Rech Agronomique Pour Le Dev Cirad Nouveaux liposomes de vaccination genique
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
NZ611427A (en) 2010-12-06 2015-08-28 Penn State Res Found Compositions and methods relating to proliferative diseases
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP2647709B1 (en) 2012-04-05 2016-02-24 F. Hoffmann-La Roche AG Amine compounds for the selective preparation of biological samples
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
EP3003295A1 (en) 2013-03-15 2016-04-13 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
WO2014142995A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
KR102739894B1 (ko) 2014-04-25 2024-12-05 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
CN106572974B (zh) 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
EP3958868A4 (en) 2019-04-22 2023-01-18 The Penn State Research Foundation METHODS AND COMPOSITIONS FOR INHIBITING ALDEHYDE DEHYDROGENaseS FOR THE TREATMENT OF CANCER
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
US20230392188A1 (en) 2022-06-02 2023-12-07 Perkinelmer Health Sciences, Inc. Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966630A (en) * 1972-03-24 1976-06-29 Petrolite Corporation Use of polyquaternary ammonium methylene phosphonates in chelating or scale inhibition
US4022833A (en) * 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5220454A (en) * 1990-03-30 1993-06-15 Nikon Corporation Cata-dioptric reduction projection optical system
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE19505368A1 (de) * 1995-02-17 1996-08-22 Huels Chemische Werke Ag Amphiphile Verbindungen mit mindestens zwei hydrophilen und mindestens zwei hydrophoben Gruppen auf der Basis von Dicarbonsäurediamiden
EP0826063A1 (en) * 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
AU738384B2 (en) * 1996-11-04 2001-09-20 Qiagen Gmbh Cationic reagents for transfection

Similar Documents

Publication Publication Date Title
JP2001502561A5 (enExample)
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2002515037A5 (enExample)
JP2001507135A5 (enExample)
JP2000509396A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000504787A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2002511979A5 (enExample)
JP2000501744A5 (enExample)
JP2000505355A5 (enExample)
JP2000516071A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)